Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 12 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Revenue and all profit items exceeded the earnings forecast for the interim consolidated accounting period. In light of the results of growth investments made in fiscal 2025, the steady performance of existing businesses, growth in products including RADICAVA, cefiderocol and Quviviq, and increases in royalty income and share of profit from investments accounted for using the equity method due to strong sales by ViiV, the full-year forecast was revised upward.
| Item | Details |
|---|---|
| Net Sales | ¥700,000 million → ¥720,000 million（+2.9%） |
| Operating profit | ¥220,000 million → ¥230,000 million（+4.5%） |
| Profit attributable to owners of the parent | ¥210,000 million → ¥212,500 million（+1.2%） |
| Net income per share | ¥246.79 → ¥249.72 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 12 May 2026 |
| Previous-period results | Revenue ¥499,677 million, operating profit ¥170,306 million, profit before tax ¥242,497 million, profit for the year attributable to owners of the parent ¥209,244 million, basic earnings per share ¥245.91 |
| Reason for the revision | Revenue and all profit items exceeded the earnings forecast for the interim consolidated accounting period. In light of the results of growth investments made in fiscal 2025, the steady performance of existing businesses, growth in products including RADICAVA, cefiderocol and Quviviq, and increases in royalty income and share of profit from investments accounted for using the equity method due to strong sales by ViiV, the full-year forecast was revised upward. |
| Dividend forecast revision | The interim dividend was increased from the previous forecast of ¥38 to ¥40, the year-end dividend from ¥38 to ¥46 and the annual dividend from ¥76 to ¥86. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue and all profit items exceeded forecasts for the interim consolidated accounting period, as the results of growth investments made since fiscal 2025 and the steady performance of existing businesses drove earnings. Overseas, sales and royalty revenue related to RADICAVA, cefiderocol and ViiV grew, while sales of Quviviq and other products increased in Japan. The company also expects to expand its rare disease business through the acquisition of IntraBio and continued growth in Quviviq. The dividend increase is intended to return to shareholders the benefits of a strengthened earnings base and enhanced cash-generation capacity.